BNP Paribas Financial Markets Buys New Holdings in Smith & Nephew plc (NYSE:SNN)

BNP Paribas Financial Markets bought a new stake in Smith & Nephew plc (NYSE:SNN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 17,709 shares of the medical equipment provider's stock, valued at approximately $435,000.

Other large investors have also modified their holdings of the company. Principal Securities Inc. boosted its position in shares of Smith & Nephew by 87.6% in the 4th quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock valued at $36,000 after purchasing an additional 691 shares during the period. R Squared Ltd acquired a new stake in shares of Smith & Nephew in the 4th quarter valued at about $41,000. National Bank of Canada FI boosted its position in shares of Smith & Nephew by 36.5% in the 4th quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock valued at $41,000 after purchasing an additional 446 shares during the period. Hara Capital LLC boosted its position in shares of Smith & Nephew by 391.4% in the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock valued at $60,000 after purchasing an additional 1,957 shares during the period. Finally, Blue Trust Inc. boosted its position in shares of Smith & Nephew by 26.0% in the 4th quarter. Blue Trust Inc. now owns 5,871 shares of the medical equipment provider's stock valued at $144,000 after purchasing an additional 1,213 shares during the period. Institutional investors and hedge funds own 25.64% of the company's stock.

Smith & Nephew Price Performance

NYSE SNN traded down $0.31 during mid-day trading on Wednesday, hitting $28.61. The stock had a trading volume of 438,223 shares, compared to its average volume of 795,980. Smith & Nephew plc has a 52-week low of $23.69 and a 52-week high of $31.72. The company has a market cap of $12.53 billion, a price-to-earnings ratio of 13.25, a P/E/G ratio of 1.26 and a beta of 0.68. The company has a 50 day simple moving average of $27.45 and a 200 day simple moving average of $26.45. The company has a quick ratio of 1.11, a current ratio of 2.51 and a debt-to-equity ratio of 0.63.

Wall Street Analysts Forecast Growth

SNN has been the subject of a number of recent research reports. UBS Group cut Smith & Nephew from a "buy" rating to a "neutral" rating in a research report on Wednesday, March 12th. Hsbc Global Res cut Smith & Nephew from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. HSBC cut Smith & Nephew from a "buy" rating to a "hold" rating in a research report on Friday, April 25th. Canaccord Genuity Group raised their price target on Smith & Nephew from $27.00 to $28.00 and gave the company a "hold" rating in a report on Thursday, May 1st. Finally, Wall Street Zen raised Smith & Nephew from a "buy" rating to a "strong-buy" rating in a report on Wednesday, February 26th. Six research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $28.00.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.